Literature DB >> 9174186

In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

D Bahl1, D A Miller, I Leviton, P Gialanella, M J Wolin, W Liu, R Perkins, M H Miller.   

Abstract

We characterized the effects of ciprofloxacin and rifampin alone and in combination on Staphylococcus aureus in vitro. The effects of drug combinations (e.g., indifferent, antagonistic, or additive interactions) on growth inhibition were compared by disk approximation studies and by determining the fractional inhibitory concentrations. Bactericidal effects in log-phase bacteria and in nongrowing isolates were characterized by time-kill methods. The effect of drug combinations was dependent upon whether or not cells were growing and whether killing or growth inhibition was the endpoint used to measure drug interaction. Despite bactericidal antagonism in time-kill experiments, our in vitro studies suggest several possible explanations for the observed benefits in patients treated with a combination of ciprofloxacin and rifampin for deep-seated staphylococcal infections. Notably, when growth inhibition rather than killing was used to characterize drug interaction, indifference rather than antagonism was observed. An additive bactericidal effect was observed in nongrowing bacteria suspended in phosphate-buffered saline. While rifampin antagonized the bactericidal effects of ciprofloxacin, ciprofloxacin did not antagonize the bactericidal effects of rifampin. Each antimicrobial prevented the emergence of subpopulations that were resistant to the other.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174186      PMCID: PMC163902          DOI: 10.1128/AAC.41.6.1293

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  [Mechanism of action of quinolones].

Authors:  J T Smith
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants.

Authors:  M H Miller; M A Wexler; N H Steigbigel
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.

Authors:  R T Chow; T J Dougherty; H S Fraimow; E Y Bellin; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

Review 4.  Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy.

Authors:  A W Karchmer
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

5.  Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin.

Authors:  H F Chambers; B J Hartman; A Tomasz
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

6.  Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters.

Authors:  A Pascual; I García; E Ramirez de Arellano; E J Perea
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

7.  Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection.

Authors:  R H Eng; S M Smith; M Tillem; C Cherubin
Journal:  Arch Intern Med       Date:  1985-01

8.  Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth.

Authors:  H J Zeiler
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

9.  In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.

Authors:  C J Hackbarth; H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

View more
  9 in total

1.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

2.  Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  O Murillo; A Doménech; A Garcia; F Tubau; C Cabellos; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

3.  Use of affinity allows anti-inflammatory and anti-microbial dual release that matches suture wound resolution.

Authors:  Rebecca M Haley; Victoria R Qian; Greg D Learn; Horst A von Recum
Journal:  J Biomed Mater Res A       Date:  2019-03-20       Impact factor: 4.396

4.  Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections.

Authors:  Rafael San Juan; Ana Garcia-Reyne; Pedro Caba; Fernando Chaves; Carlos Resines; Fernando Llanos; Francisco López-Medrano; Manuel Lizasoain; Jose Maria Aguado
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 5.  Predictors of mortality in Staphylococcus aureus Bacteremia.

Authors:  Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

6.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

7.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

8.  Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon.

Authors:  Y Ouadrhiri; B Scorneaux; Y Sibille; P M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

9.  Antibiotic combinations reduce Staphylococcus aureus clearance.

Authors:  Viktória Lázár; Olga Snitser; Daniel Barkan; Roy Kishony
Journal:  Nature       Date:  2022-10-05       Impact factor: 69.504

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.